Skip to main content
. 2023 Mar 1;11(3):564. doi: 10.3390/vaccines11030564

Table 1.

Characteristics of study participants, stratified by the COVID-19 vaccine regimen.

Characteristics a CoronaVac/
CoronaVac
AZD1222/
AZD1222
CoronaVac/
AZD1222
AZD1222/
BNT162b2
BNT162b2/
BNT162b2
P b
Number of enrolled participants 332 221 110 128 110
Age, years 39.0 (30.0–48.0) 62.6 (52.3–68.3) 59.8 (44.0–65.2) 52.3 (30.7–67.5) 28.7 (22.8–36.9) <0.001
Age category <0.001
<60 years 332 (100) 73 (33.0) 55 (50.0) 73 (57.0) 110 (100)
≥60 years 0 (0) 148 (67.0) 55 (50.0) 55 (43.0) 0 (0)
Sex 0.003
Male 90 (27.1) 81 (36.7) 48 (43.6) 44 (34.4) 27 (24.6)
Female 242 (72.9) 140 (63.3) 62 (56.4) 84 (65.6) 83 (75.4)
Body mass index, kg/m2 23.1 (20.9–26.0) 24.7 (22.0–27.3) 27.4 (23.7–35.0) 23.2 (20.3–26.2) 22.5 (19.8–26.6) <0.001
Body mass index category <0.001
Underweight 20 (6.0) 10 (4.5) 2 (1.8) 8 (6.3) 14 (12.7)
Normal weight 201 (60.6) 108 (48.9) 40 (36.4) 78 (60.9) 56 (50.9)
Overweight 80 (24.1) 75 (33.9) 36 (32.7) 34 (26.6) 28 (25.5)
Obese 31 (9.3) 28 (12.7) 32 (29.1) 8 (6.2) 12 (10.9)
Cigarette smoking <0.001
Never smoked 326 (98.2) 197 (89.1) 88 (80.0) 120 (93.8) 103 (93.6)
Ever smoked (current and former) 6 (1.8) 24 (10.9) 22 (20.0) 8 (6.2) 7 (6.4)
Alcohol consumption <0.001
Never drunk 287 (86.5) 168 (76.0) 71 (64.6) 100 (78.1) 87 (79.1)
Ever drunk (current and former) 45 (13.5) 53 (24.0) 39 (35.4) 28 (21.9) 23 (20.9)

Abbreviations: AZD1222 vaccine, the Oxford-AstraZeneca COVID-19 vaccine; BNT162b2; Pfizer-BioNTech vaccine; COVID-19, coronavirus disease 2019; a Data were presented as number (percentage) for categorical data and median (interquartile range) for continuous data; b The comparisons across five COVID-19 vaccine regimens were performed by the Chi-squared test or the Fisher’s exact test (if less than five observations) for categorical data and by the Wilcoxon rank-sum test for continuous data.